Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064819 | 1.00 | TYMS (0.40) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7601149 | 0.93 | TYMS (0.39) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7602647 | 0.92 | TYMS (0.38) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7602877 | 0.91 | TYMS (0.39) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7602019 | 0.91 | TYMS (0.39) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7598036 | 0.89 | TYMS (0.38) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7602777 | 0.89 | TYMS (0.38) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7598505 | 0.87 | TK1 (0.42) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL7605414 | 0.87 | CYP1A2 (0.38) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL8762964 | 0.86 | TYMS (0.31) | TYMSCYP1A2CYP3A4TSHRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| WO-2006010084-A2 | A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TYMS 776/4885CYP1A2 4664/4885CYP3A4 4440/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TYMS 776/4885CYP1A2 4664/4885CYP3A4 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.